Wednesday May 15, 2013 0 commentsDENVER - Sorin Group (MIL: SRN), a global medical company and a leader in the treatment of cardiovascular diseases, has received FDA approval for and is beginning the U.S. launch of its SMARTVIEW remote monitoring solution for patients with implanted cardiac rhythm management devices, the company announced.
The SMARTVIEW solution allows physicians and nurses following patients with a Sorin PARADYM RF device to access cardiac data and alert messages from the device while the patient is at home.
Sorin launched the PARADYM RF VR and DR implantable cardioverter-defibrillators and cardiac resynchronization therapy devices in the U.S. in May 2012.
Installation of the SMARTVIEW remote monitoring system at the patient's home is assisted by a dedicated help desk provided by Sorin. Once the system is installed, patients use it to transmit data electronically from their implanted cardiac device to their physicians.
"The introduction of SMARTVIEW remote monitoring in the United States is an important milestone for Sorin as we seek to extend our innovative technology offerings to more U.S. health care providers and patients," said Stefano Di Lullo, Sorin's CRM business unit president.
"We believe our intelligent devices and first-rate remote monitoring capabilities and service will continue to help us grow our business in the United States while, most importantly, saving lives and improving patient symptoms."
For more information, visit www.sorin.com.